Table 4

Sensitivity analysis for patients treated with the cilostazol-based combination

Crude HR (95% CI)P valueAdjusted HR
(95% CI)
P valueIPTW,* weighted HR
(95% CI)
P value
Primary outcome
 Cilostazol-based combination1 (ref.)1 (ref.)1 (ref.)
 Aspirin monotherapy0.97 (0.77 to 1.22)0.791.14 (0.90 to 1.44)0.270.99 (0.71 to 1.39)0.97
 Clopidogrel–aspirin0.87 (0.69 to 1.10)0.240.89 (0.71 to 1.13)0.340.78 (0.56 to 1.08)0.14
All strokes
 Cilostazol-based combination1 (ref.)1 (ref.)1 (ref.)
 Aspirin monotherapy0.91 (0.73 to 1.15)0.441.08 (0.85 to 1.36)0.550.93 (0.67 to 1.30)0.67
 Clopidogrel–aspirin0.82 (0.65 to 1.04)0.100.84 (0.67 to 1.07)0.160.73 (0.52 to 1.02)0.07
All-cause mortality
 Cilostazol-based combination1 (ref.)1 (ref.)1 (ref.)
 Aspirin monotherapy7.70 (1.08 to 55.09)0.049.16 (1.26 to 66.44)0.0315.75 (2.18 to 113.77)0.006
 Clopidogrel–aspirin6.79 (0.95 to 48.80)0.066.68 (0.92 to 48.48)0.0611.67 (1.61 to 84.53)0.02
 Cilostazol-based combination1(ref.)
 Aspirin monotherapy1.75 (0.09 to 32.65)0.71Non-estimableNon-estimable
 Clopidogrel–aspirin2.92 (0.16 to 53.48)0.47Non-estimableNon-estimable
  • Adjusted variables: age; male sex; initial NIHSS score; arrival time; TOAST classification; history of TIA, stroke, CAD and PAD; HTN; DM; dyslipidaemia; smoking; atrial fibrillation; prior antiplatelet, antihypertensive, antidiabetic, statin or lipid-lowering agent use; multiple lesions; LASO; discharge medications of antihypertensives, antidiabetics, statins and lipid-lowering agents; creatinine; haemoglobin; platelet count; LDL cholesterol; glucose; and SBP.

  • *Weighted Cox proportional hazards model with robust standard errors.

  • †Cox proportional hazards regression using Firth’s penalised maximum likelihood method.

  • CAD, coronary artery disease; DM, diabetes mellitus; HTN, hypertension; IPTW, inverse probability of treatment weighting; LASO, large artery stenosis/occlusion; LDL, low-density lipoprotein; LDL, low-density lipoprotein; NIHSS, National Institutes of Health Stroke Scale; PAD, peripheral artery disease; TIA, transient ischemic attack; TOAST, Trial of Org 10 172 in Acute Stroke Treatment.